A peptide that binds a receptor becomes an imaging or therapy agent when a radiometal is attached to it. The attachment is not a label in the usual sense — it is a cage, and the cage has to hold a metal ion tightly enough that none of it ends up anywhere else. Choosing that cage involves three constraints that pull against each other: the metal's coordination chemistry, the isotope's half-life, and how much heat the peptide will survive. This page sets out how those three interact and what has to be specified when ordering the conjugate.
It has two jobs at once: coordinate the metal ion with high thermodynamic stability and kinetic inertness, and carry a handle for attachment to the peptide. The two requirements interact more than they look. A chelator that holds the metal through four carboxylate arms has to give one of them up to form an amide bond with the peptide — and the resulting molecule is chemically a different chelator from the one in the catalogue.
DOTA is the general-purpose answer and the clinical standard. It forms stable complexes with a long list of radiometals — gallium-68, copper-64, yttrium-90, lutetium-177, actinium-225 among them1 — and that breadth is exactly why it dominates: one conjugate can serve both halves of a matched imaging-and-therapy pair.
Its weakness is specific and well documented. DOTA's twelve-membered ring does not match the coordination preferences of Ga3+ especially well, and labelling it with gallium-68 requires heating to roughly 80–100 °C2. The smaller nine-membered NOTA ring suits Ga3+ better, and NOTA and its derivative NODAGA label faster and under milder conditions — in one side-by-side comparison, roughly twice the radiochemical yield and better label stability than DOTA for gallium-685. That comparison used a DARPin rather than a peptide, so treat the factor as indicative rather than transferable. For zirconium-89, desferrioxamine (DFO) labels at room temperature in aqueous conditions and remains the established choice for antibody work3. It is worth knowing its limitation: DFO is hexadentate, whereas Zr(IV) prefers eight-coordination, and the resulting complex is not fully stable in vivo — which is why octadentate derivatives such as DFO* were developed and why chelator choice here is still an active question3.
Gallium-68 has a half-life of about 68 minutes2. Every minute spent on the labelling step costs activity that cannot be recovered, which is why a chelator that labels in five minutes at room temperature has a substantial practical advantage over one requiring half an hour at 95 °C. That logic does not apply to lutetium-177 or zirconium-89, where the half-lives are measured in days and a slower, hotter step is affordable.
This is also why the field pushes towards "cold kit" formulations — a single-vial reagent that a hospital can label without automated synthesis equipment. The DOTA labelling protocols in that review call for heating in the region of 90 °C, which is why DOTA peptides are described as a poor candidate for kit-based radiopharmacy; the temperature, time and yield that a given construct needs depend on the isotope, the chelator derivative and the formulation, so the figure is a typical condition rather than a fixed threshold. NOTA, TRAP and tris(hydroxypyridinone) chelators label efficiently at near-neutral pH and room temperature4. The counterweight, stated in the same review, is that DOTA and its derivatives still remain the chelator of choice even for gallium-68. The reason is coordination chemistry rather than convenience: most of the faster alternatives cannot complex the higher-coordination-number radiometals — lutetium-177, yttrium-90, actinium-225 — that the therapeutic half of a theranostic pair requires4. Breadth beats speed when the same molecule has to carry two different metals.
For peptides, temperature is often the constraint that decides. A heat-sensitive targeting vector forces a balance between labelling temperature and vector stability3. A peptide containing methionine, tryptophan, cysteine or an Asp-Gly motif is at risk of oxidation, epimerisation or aspartimide formation during fifteen minutes at 95 °C in acid. Where the peptide cannot tolerate those conditions, the chelator choice has already been made — and it is worth establishing that before committing to a conjugate, not afterwards.
This is the detail most often missed. The chelating moiety in compounds routinely called "DOTA-peptides" is not DOTA at all but DOTA-monoamide, because one of the four acetate arms has been consumed forming the bond to the peptide — and DOTA-monoamide shows different Ga3+ complexation behaviour from DOTA itself1. Published labelling data for free DOTA therefore does not transfer directly to a DOTA-peptide.
Bifunctional chelators designed for the job avoid this. In NODAGA and in TRAP, the attachment handle is a separate arm, so the structure of the chelating site is unaffected by conjugation1. If labelling performance matters more than catalogue familiarity, that distinction is worth paying attention to when the conjugate is specified.
A chelator is a bulky, highly charged macrocycle. Placed next to the binding region of a short peptide it can interfere, and the metal complex it forms afterwards changes the charge again; the effect of a given attachment point has to be tested rather than predicted. Two rules follow.
Newer chelators continue to shift the trade-off: one AAZTA derivative conjugated to a PSMA-targeting vector achieved quantitative labelling — above 99% in under five minutes at room temperature — with gallium-68, scandium-44 and lutetium-177 alike6, which is the combination of breadth and mildness the field has been working towards.
| Ga-68 | NOTA or NODAGA label mild and fast; DOTA works but needs 80–100 °C |
| Lu-177, Y-90 | DOTA — the clinical standard, hot labelling acceptable |
| Zr-89 | DFO, mild conditions |
| Watch for | A "DOTA-peptide" is really a DOTA-monoamide |
| Placement | Far end from the binding region, with a defined spacer |
LifeTein synthesises chelator-conjugated peptides for research use: DOTA, DOTA-GA, NOTA, NODAGA and DFO coupled at a specified terminus or lysine, with orthogonal protection where only one of several lysines should react, defined PEG or aminohexanoic acid spacers, and purification handled with trace-metal contamination in mind. We supply the non-radioactive conjugate and its cold metal-complex reference standard; radiolabelling is carried out at your own radiochemistry facility. All material is for research use.